Low dose aspirin and cognitive function in the women's health study cognitive cohort

British Medical Journal

Volumn 334, Issue 7601, 2007, Pages 987-990

  Kang, Jae Hee ^a   Cook, Nancy ^a   Manson, JoAnn ^a   Buring, Julie E ^a   Grodstein, Francine ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; PLACEBO;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERBAL MEMORY; WOMEN'S HEALTH;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COHORT STUDIES; HEALTH STATUS; HUMANS; MALE; MEMORY DISORDERS; NOOTROPIC AGENTS; PSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 34249293021     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39166.597836.BE     Document Type: Article

References (27)

1. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population based sample. Arch Neurol 2000;57:839-44.
2. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128:1093-101.
3. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
4. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
5. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 2000;54:588-93.
6. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455-60.
7. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
8. Couzin J. Halt of Celebrex study threatens drug's future, other trials. Science 2004;306:2170.
9. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing physician's health study. N Engl J Med 1989;321:129-35.
10. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
11. Buring JE, Hennekens CH. The women's health study: summary of the design. J Myocardial Ischemia 1992;4:27-9.
12. Fitzmaurice GM, Laird NM, Ware JH. Modelling the mean: analyzing response profiles. Applied longitudinal analysis. Hoboken, NJ: John Wiley, 2004:103-39.
13. Roman GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(Suppl3):S69-80.
14. Devore E, Buring JE, Grodstein F. Plasma cholesterol levels and cognitive function in older women [abstract]. Neurobiol Aging 2004;25(Suppl2):S52.
15. Lee S, Buring JE, Cook NR, Grodstein F. The relation of education and income to cognitive function among professional women. Neuroepidemiology 2006;26:93-101.
16. De Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114-20.
17. Kang JH, Grodstein F. Regular use of non-steroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 2003;60:1591-7.
18. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22:2142-7.
19. Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH. Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;143:683-91.
20. Jonker C, Comijs HC, Smit JH. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 2003;24:583-8.
21. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE. Antiplatelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996;3:209-12.
22. Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998;51:986-93.
23. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 2001;414:212-6.
24. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA 1995;274:1846-51.
25. Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, et al. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham study. Diabetes Care 1997;20:1388-95.
26. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly persons. JAMA 1998;50:1580-5.
27. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2002;322:1447-51.